The European Medicines Agency announced Tuesday that they have begun a rolling review of the coronavirus vaccine developed by the China-based Sinovac Life Sciences Ltd.
The vaccine, called the COVID-19 Vacine (Vero Cell) Inactivated would be different than the Pfizer and Moderna shots which use mRNA instead of an inactivated virus.
The statement released by the EMA states that decision from the Committee for Medicinal Products for Human Use to begin reviews comes from promising non-clinical preliminary lab studies in addition to clinical studies. These studies are showing that the vaccine does indeed triggers the production of antibodies that fight the COVIS_19 causing SARV-CoV-2 virus.
The EMA says they will evaluate data as is becomes available to weigh the benefits and risks of the vaccine, and will continue until "enough evidence is available for a formal marketing authorization application."
The agency also states that the evaluation should take less time than normal due to the use of a rolling review, and will assess the vaccine's compliance with EU standards.
The announcement from the EMA comes just one day after a top World Health Organization official said that, according to The Associated Press, the WHO is set to decide on the approval of two Chinese COVID-19 vaccines, Sinopharm and Sinovac, for emergency use. This would mark the first time the UN would allow a Chinese vaccine for emergency use.
Join and support independent free thinkers!
We’re independent and can’t be cancelled. The establishment media is increasingly dedicated to divisive cancel culture, corporate wokeism, and political correctness, all while covering up corruption from the corridors of power. The need for fact-based journalism and thoughtful analysis has never been greater. When you support The Post Millennial, you support freedom of the press at a time when it's under direct attack. Join the ranks of independent, free thinkers by supporting us today for as little as $1.
Remind me next month
To find out what personal data we collect and how we use it, please visit our Privacy Policy
